Found 4 matching trials
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) PHASE2 The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Re...
Show More Learn More & Join Trial
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies PHASE1 Effective treatment options for relapsed/refractory acute myeloid leukemia ...
Show More Location
Washington University School of Medicine
Learn More & Join Trial
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL PHASE1 The purpose of this study is to evaluate the safety, recommended dose, and ...
Show More Learn More & Join Trial
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 N/A This study will provide long-term follow-up for patients who have received ...
Show More Status
Enrolling By Invitation
Learn More & Join Trial